Background Background It is uncertain whether
It is uncertain whether higher doses of selective serotonin higher doses of selective serotonin reuptake inhibitors have greater efficacyin reuptake inhibitors have greater efficacyin generalised anxiety disorder. generalised anxiety disorder.
Aims Aims To assess the efficacy of different
To assess the efficacy of different doses of escitalopram in generalised doses of escitalopram in generalised anxiety disorder. anxiety disorder.
Method
Method Randomised, double-blind, Randomised, double-blind, placebo-controlled, fixed-dose, parallelplacebo-controlled, fixed-dose, parallelgroup,12-week study, with 681patients: group,12-week study, with 681patients: placebo ( placebo (n n¼139); escitalopram, 5 mg/day, 139); escitalopram, 5 mg/day, ( (n n¼134); 10 mg/day ( 134); 10 mg/day (n n¼136); 20 mg/day 136); 20 mg/day ( (n n¼133); paroxetine, 20 mg/day ( 133); paroxetine, 20 mg/day (n n¼139). 139).
Results
Results Mean change in the primary Mean change in the primary efficacy measure was greater with efficacy measure was greater with escitalopram10 and 20 mg than with escitalopram10 and 20 mg than with placebo; 10 mg was more efficacious than placebo; 10 mg was more efficacious than paroxetine. Paroxetine was superior to paroxetine.Paroxetine was superior to placebo on some secondary measures, at placebo on some secondary measures, at some time points.Compared with some time points.Compared with placebo, more patients withdrew because placebo, more patients withdrew because of adverse events with escitalopram of adverse events with escitalopram 20 mg and paroxetine. 20 mg and paroxetine.
Some selective serotonin reuptake inhibiSome selective serotonin reuptake inhibitors (SSRIs) and benzodiazepines, and the tors (SSRIs) and benzodiazepines, and the serotonin-noradrenaline reuptake inhibitor serotonin-noradrenaline reuptake inhibitor venlafaxine, are efficacious in generalised venlafaxine, are efficacious in generalised anxiety disorder (Baldwin & Polkinghorn, anxiety disorder (Baldwin & Polkinghorn, 2005) . Placebo-controlled double-blind stu-2005). Placebo-controlled double-blind studies demonstrate the efficacy of the SSRIs dies demonstrate the efficacy of the SSRIs paroxetine (Pollack paroxetine (Pollack et al et al, 2001; Rickels , 2001; Rickels et al et al, 2003) , sertraline (Allgulander , 2003) , sertraline (Allgulander et al et al, , 2004; Brawman-Mintzer 2004; Brawman-Mintzer et al et al, 2006), and , 2006) , and escitalopram (Davidson escitalopram (Davidson et al et al, 2004; Good-, 2004; Goodman man et al et al, 2005) . A 24-week study found , 2005) . A 24-week study found escitalopram (10-20 mg/day) and paroxeescitalopram (10-20 mg/day) and paroxetine (20-50 mg/day) to have similar efficacy tine (20-50 mg/day) to have similar efficacy (Bielski (Bielski et al et al, 2005) . These studies provide , 2005). These studies provide no clear evidence for a dose-response no clear evidence for a dose-response relationship. Current guidelines for relationship. Current guidelines for assessing efficacy recommend a minimum assessing efficacy recommend a minimum length of 8 weeks, using a placebolength of 8 weeks, using a placebocontrolled design comprising fixed doses controlled design comprising fixed doses to establish optimal dosage (Montgomery to establish optimal dosage (Montgomery & van Zwieten-Boot, 2002) . This study & van Zwieten-Boot, 2002) . This study aimed to compare the efficacy of fixed aimed to compare the efficacy of fixed doses of escitalopram (5, 10 or 20 mg/day) doses of escitalopram (5, 10 or 20 mg/day) with placebo over 12 weeks' treatment, inwith placebo over 12 weeks' treatment, including paroxetine (20 mg/day) as an active cluding paroxetine (20 mg/day) as an active reference. reference.
METHOD METHOD Study design and closing schedule Study design and closing schedule
This randomised, placebo-controlled, fixedThis randomised, placebo-controlled, fixeddose, active-reference study included 63 dose, active-reference study included 63 centres in 10 countries. It was conducted centres in 10 countries. It was conducted in accordance with the principles of in accordance with the principles of Good Good Clinical Practice Clinical Practice (ICH, 1996) and the (ICH, 1996) and the Declaration of Helsinki Declaration of Helsinki (World Medical (World Medical Association, 2000) . Local ethics commitAssociation, 2000) . Local ethics committees approved the study design, and eligible tees approved the study design, and eligible patients gave their written informed conpatients gave their written informed consent before participating. After screening, sent before participating. After screening, patients entered a 1-week, single-blind, patients entered a 1-week, single-blind, placebo lead-in period before being placebo lead-in period before being randomised to 12 weeks of double-blind randomised to 12 weeks of double-blind treatment with fixed doses of escitalopram treatment with fixed doses of escitalopram (5, 10 or 20 mg/day), paroxetine (20 mg/ (5, 10 or 20 mg/day), paroxetine (20 mg/ day), or placebo. Patients who completed day), or placebo. Patients who completed double-blind treatment entered a randomdouble-blind treatment entered a randomised staggered 2-week (1-week doubleised staggered 2-week (1-week doubleblind, then 1-week single-blind) placebo blind, then 1-week single-blind) placebo wash-out period. Efficacy and tolerability wash-out period. Efficacy and tolerability were assessed at baseline and after 1, 2, 4, were assessed at baseline and after 1, 2, 4, 6, 8, 10, 12, 13 and 14 weeks; a safety 6, 8, 10, 12, 13 and 14 weeks; a safety follow-up visit was performed 14 days after follow-up visit was performed 14 days after the last wash-out visit. the last wash-out visit.
Allocation to treatment Allocation to treatment
Study medications were capsules for oral Study medications were capsules for oral administration, of identical appearance, administration, of identical appearance, taste and smell. The oxalate salt of escitalotaste and smell. The oxalate salt of escitalopram was used in the capsules. Patients pram was used in the capsules. Patients who met selection criteria at the screening who met selection criteria at the screening and baseline visits were assigned to 12 and baseline visits were assigned to 12 weeks of double-blind treatment in a weeks of double-blind treatment in a 1:1:1:1:1 ratio of 5 mg escitalopram to 1:1:1:1:1 ratio of 5 mg escitalopram to 10 mg escitalopram to 20 mg escitalopram 10 mg escitalopram to 20 mg escitalopram to 20 mg paroxetine to placebo according to 20 mg paroxetine to placebo according to a computer-generated randomisation list to a computer-generated randomisation list drawn up by H. Lundbeck A/S. The timing drawn up by H. Lundbeck A/S. The timing of down-titration for the 5 mg and 10 mg of down-titration for the 5 mg and 10 mg escitalopram groups and the 20 mg parescitalopram groups and the 20 mg paroxetine group was built into the overall oxetine group was built into the overall randomisation scheme; patients in these randomisation scheme; patients in these groups were assigned to continue current groups were assigned to continue current active treatment or start placebo wash-out active treatment or start placebo wash-out treatment at week 13 in a 1:1 ratio of active treatment at week 13 in a 1:1 ratio of active treatment to placebo. The details of the treatment to placebo. The details of the randomisation series were unknown to randomisation series were unknown to any of the investigators and were contained any of the investigators and were contained in a set of sealed opaque envelopes. At each in a set of sealed opaque envelopes. At each study centre, sequentially enrolled patients study centre, sequentially enrolled patients were assigned the lowest randomisation were assigned the lowest randomisation number available in blocks of ten. All study number available in blocks of ten. All study personnel and participants were masked to personnel and participants were masked to treatment assignment for the duration of treatment assignment for the duration of the study. the study.
Patient population Patient population
The selection criteria were chosen to The selection criteria were chosen to select physically healthy male and female select physically healthy male and female out-patients with a primary diagnosis of out-patients with a primary diagnosis of generalised anxiety disorder according generalised anxiety disorder according to DSM-IV-TR (American Psychiatric to DSM-IV-TR (American Psychiatric Association, 2000) criteria. The Mini Association, 2000) criteria. The Mini International Neuropsychiatric Interview International Neuropsychiatric Interview (MINI: Sheehan (MINI: Sheehan et al et al, 1998) was used to , 1998) was used to establish the diagnosis and to confirm the establish the diagnosis and to confirm the 2 6 4 2 6 4 B R I T I S H J O UR N A L O F P SYC HI AT RY B R I T I S H J O UR N A L O F P S YC H I AT RY ( 2 0 0 6 ) , 1 8 9, 2 6 4^2 7 2 . d o i : 1 0 .11 9 2 / b j p . b p .1 0 5 . 0 1 2 7 9 9 ( 2 0 0 6 ) , 1 8 9, 2 6 4^2 7 2 . d o i : 1 0 .11 9 2 / b j p . b p .1 0 5 . 0 1 2 7 9 9
Escitalopram and paroxetine in the treatment 52 on both HAMA item 1 2 on both HAMA item 1 (anxious mood) and item 2 (tension) at (anxious mood) and item 2 (tension) at screening and at baseline could be screening and at baseline could be included. A low level of depressive included. A low level of depressive symptoms was allowed using the symptoms was allowed using the Montgomery-Asberg Depression Rating Montgomery-Å sberg Depression Rating Scale (MADRS; Montgomery & Asberg, Scale (MADRS; Montgomery & Å sberg, 1979) , i.e. total score 1979), i.e. total score 4 416 at screening 16 at screening and at baseline. and at baseline.
Patients with the following disorders Patients with the following disorders within the previous 6 months (based on within the previous 6 months (based on DSM-IV-TR criteria, confirmed using the DSM-IV-TR criteria, confirmed using the MINI) were excluded: major depressive MINI) were excluded: major depressive disorder, panic disorder, social anxiety disorder, panic disorder, social anxiety disorder, post-traumatic stress disorder, disorder, post-traumatic stress disorder, bipolar disorder, obsessive-compulsive disbipolar disorder, obsessive-compulsive disorder, eating disorders, body dysmorphic order, eating disorders, body dysmorphic disorder, substance misuse disorder, any disorder, substance misuse disorder, any personality disorder that could jeopardise personality disorder that could jeopardise the evaluation of the treatment for primary the evaluation of the treatment for primary generalised anxiety, as judged by the generalised anxiety, as judged by the investigator, and any current or previous investigator, and any current or previous psychotic disorder as defined by DSM-IVpsychotic disorder as defined by DSM-IV-TR. Patients were also excluded if TR. Patients were also excluded if they were at risk of suicide (according to they were at risk of suicide (according to the investigator's judgement), had a score the investigator's judgement), had a score 4 43 on item 10 (suicidal thoughts) of 3 on item 10 (suicidal thoughts) of the MADRS, or had made a serious the MADRS, or had made a serious suicide attempt within the past year or were suicide attempt within the past year or were receiving cognitive-behavioural therapy, receiving cognitive-behavioural therapy, electroconvulsive therapy, cognitive therapy electroconvulsive therapy, cognitive therapy or problem-solving treatment, or planned to or problem-solving treatment, or planned to initiate such therapy. Furthermore, patients initiate such therapy. Furthermore, patients with an unstable serious illness and/or serwith an unstable serious illness and/or serious sequelae of liver or renal insufficiency, ious sequelae of liver or renal insufficiency, or cardiac, vascular, pulmonary, gastroor cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurological, infecintestinal, endocrine, neurological, infectious, neoplastic or metabolic disturbance tious, neoplastic or metabolic disturbance were also excluded. Patients were excluded were also excluded. Patients were excluded if they had taken psychoactive subif they had taken psychoactive substances, anxiolytics, antidepressants, monostances, anxiolytics, antidepressants, monoamine oxidase inhibitors, benzodiazepines, amine oxidase inhibitors, benzodiazepines, b b-blockers (use of anti-hypertensives other -blockers (use of anti-hypertensives other than than b b-blockers was permitted as long -blockers was permitted as long as the dose had been stable for 6 months as the dose had been stable for 6 months and remained fixed during the study), and remained fixed during the study), tryptophan, oral antipsychotics, narcotic tryptophan, oral antipsychotics, narcotic analgesics (except intermittent use of analgesics (except intermittent use of codeine-based analgesics), warfarin sodium, codeine-based analgesics), warfarin sodium, digitalis, cardiac glycosides, type 1c antidigitalis, cardiac glycosides, type 1c antiarrhythmics, phenytoin, cimetidine, regular arrhythmics, phenytoin, cimetidine, regular daily therapy with any hypnotic (except daily therapy with any hypnotic (except zolpidem, zopiclone, or zaleplon for insomzolpidem, zopiclone, or zaleplon for insomnia, but not more than 3 times per week), nia, but not more than 3 times per week), psychoactive herbal remedies, antiepileppsychoactive herbal remedies, antiepileptics, ongoing prophylactic treatment with tics, ongoing prophylactic treatment with lithium, valproate or carbamazepine, and lithium, valproate or carbamazepine, and triptans within the 2 weeks before the triptans within the 2 weeks before the screening visit, and any investigational drug screening visit, and any investigational drug or depot antipsychotics within 6 months or depot antipsychotics within 6 months before the screening visit. before the screening visit.
Efficacy assessments Efficacy assessments
The primary end-point was defined as The primary end-point was defined as the adjusted mean change in HAMA total the adjusted mean change in HAMA total score from baseline to week 12, based score from baseline to week 12, based on the intention-to-treat set and using on the intention-to-treat set and using lastlast-observation-carried-forward analysis.
observation-carried-forward analysis. Secondary efficacy measures included: Secondary efficacy measures included: change from baseline in HAMA total score change from baseline in HAMA total score at each visit; Clinical Global Impressionat each visit; Clinical Global ImpressionSeverity (CGI-S) and Clinical Global Severity (CGI-S) and Clinical Global Impression -Improvement (CGI-I; Guy, Impression -Improvement (CGI-I; Guy, 1976) score per visit; proportion of respon-1976) score per visit; proportion of responders per visit using two criteria ( ders per visit using two criteria (5 550% 50% reduction in HAMA total score compared reduction in HAMA total score compared with baseline, and CGI-I score of 1 and with baseline, and CGI-I score of 1 and 2); proportion of remitters (HAMA total 2); proportion of remitters (HAMA total score score 4 47) per visit; and change from 7) per visit; and change from baseline in the self-rating Hospital Anxiety baseline in the self-rating Hospital Anxiety and Depression Scale (HAD; Zigmond & and Depression Scale (HAD; Zigmond & Snaith, 1983) anxiety sub-scale score at Snaith, 1983) anxiety sub-scale score at weeks 6 and 12. The investigators were weeks 6 and 12. The investigators were trained by a physician experienced in trained by a physician experienced in the use of HAMA before inclusion of the use of HAMA before inclusion of patients into the study to increase interpatients into the study to increase interrater reliability. Patient ratings were rater reliability. Patient ratings were conducted by the same person at each visit, conducted by the same person at each visit, whenever possible. whenever possible.
Tolerability assessments Tolerability assessments
Tolerability was based on the incidence of Tolerability was based on the incidence of adverse events throughout the study. The adverse events throughout the study. The Discontinuation Emergent Signs and SympDiscontinuation Emergent Signs and Symptoms (DESS) scale is a 43-item checklist toms (DESS) scale is a 43-item checklist (Rosenbaum (Rosenbaum et al et al, 1998) designed to assess , 1998) designed to assess possible treatment-related discontinuation possible treatment-related discontinuation symptoms. For this study, the DESS was symptoms. For this study, the DESS was slightly modified to include four extra slightly modified to include four extra items, reported after stopping SSRI treatitems, reported after stopping SSRI treatment: vivid dreams, electric shock-like ment: vivid dreams, electric shock-like sensations, somnolence, and feeling tense. sensations, somnolence, and feeling tense. An event was considered discontinuation An event was considered discontinuation emergent if it appeared during the previous emergent if it appeared during the previous 7 days, or if a previously reported event had 7 days, or if a previously reported event had worsened. The modified DESS was assessed worsened. The modified DESS was assessed at week 12 and during the wash-out period at week 12 and during the wash-out period (weeks 13 and 14) for patients who had (weeks 13 and 14) for patients who had completed the 12-week double-blind treatcompleted the 12-week double-blind treatment period. Unresolved symptoms in ment period. Unresolved symptoms in the DESS checklist were subject to enquiry the DESS checklist were subject to enquiry at the safety follow-up visit. Half of at the safety follow-up visit. Half of the patients randomised to escitalopram the patients randomised to escitalopram 5 or 10 mg/day, or 20 mg/day paroxetine, 5 or 10 mg/day, or 20 mg/day paroxetine, received placebo during the 2-week washreceived placebo during the 2-week washout period, whereas the other half continout period, whereas the other half continued on active treatment for 1 week (week ued on active treatment for 1 week (week 13) and received placebo for the second 13) and received placebo for the second week (week 14). Patients who were week (week 14). Patients who were randomised to 20 mg escitalopram were randomised to 20 mg escitalopram were down-titrated to 10 mg escitalopram for down-titrated to 10 mg escitalopram for 1 week (week 13) before they received 1 week (week 13) before they received placebo (week 14). placebo (week 14).
Statistical analysis Statistical analysis
A minimum of 130 patients in each A minimum of 130 patients in each treatment group (intention-to-treat) was treatment group (intention-to-treat) was expected to provide a standardised effect expected to provide a standardised effect size of 0.35, that is a significant treatment size of 0.35, that is a significant treatment difference from placebo of at least 35% of difference from placebo of at least 35% of the pooled standard deviation when comthe pooled standard deviation when comparing the mean change from baseline to paring the mean change from baseline to week 12 (last observation carried forward) week 12 (last observation carried forward) in HAMA total score, using a two-sided in HAMA total score, using a two-sided t t-test with 80% power at a 5% level of -test with 80% power at a 5% level of significance. significance.
All efficacy analyses were conducted on All efficacy analyses were conducted on the intention-to-treat population consisting the intention-to-treat population consisting of all randomised patients who took at least of all randomised patients who took at least one dose of double-blind study medication one dose of double-blind study medication and who had at least one valid postand who had at least one valid postbaseline assessment of the HAMA. The baseline assessment of the HAMA. The prospectively defined primary efficacy prospectively defined primary efficacy end-point was the adjusted mean change end-point was the adjusted mean change from baseline in HAMA total score at week from baseline in HAMA total score at week 12, based on intention to treat (last obser-12, based on intention to treat (last observation carried forward). Comparisons of vation carried forward). Comparisons of the primary efficacy end-point between the primary efficacy end-point between escitalopram and placebo were made using escitalopram and placebo were made using analysis of covariance (ANCOVA) with analysis of covariance (ANCOVA) with treatment and centre as fixed factors, and treatment and centre as fixed factors, and with the baseline HAMA total score as a with the baseline HAMA total score as a covariate. To adjust for multiple testing, covariate. To adjust for multiple testing, an an F F-test was used to test the overall null -test was used to test the overall null hypothesis of equal mean changes in the hypothesis of equal mean changes in the three escitalopram groups and the placebo three escitalopram groups and the placebo group. If the overall group. If the overall F F-test was significant -test was significant at the 5% level, pairwise comparisons of at the 5% level, pairwise comparisons of each of the three escitalopram dose groups each of the three escitalopram dose groups and the placebo group were made using and the placebo group were made using two-sided two-sided t t-tests with the overall mean -tests with the overall mean square error as the error term at a 5% level square error as the error term at a 5% level of significance. Likewise, paroxetine was of significance. Likewise, paroxetine was compared pairwise with the other treatcompared pairwise with the other treatment groups using two-sided ment groups using two-sided t t-tests with -tests with the overall mean square error as the error the overall mean square error as the error term at a 5% level of significance. term at a 5% level of significance.
The secondary efficacy analyses of The secondary efficacy analyses of mean change from baseline to each visit in mean change from baseline to each visit in the HAMA total scores and HAD sub-scale the HAMA total scores and HAD sub-scale score were analysed by ANCOVA (obscore were analysed by ANCOVA (observed cases and last observation carried served cases and last observation carried forward) using the model described for the forward) using the model described for the primary analysis. The CGI-I scores were primary analysis. The CGI-I scores were analysed using analysis of variance. Beanalysed using analysis of variance. Between-group comparisons of patients contween-group comparisons of patients considered to be treatment responders and sidered to be treatment responders and between patients considered to be remitters between patients considered to be remitters were carried out using Fisher's exact test. were carried out using Fisher's exact test.
Incidences of adverse events were comIncidences of adverse events were compared between treatment groups using pared between treatment groups using Fisher's exact test based on all randomised Fisher's exact test based on all randomised patients who took at least one dose of patients who took at least one dose of double-blind medication. double-blind medication.
The modified DESS total scores during The modified DESS total scores during the wash-out period were analysed for the wash-out period were analysed for patients completing the study based on patients completing the study based on observed cases using ANCOVA with treatobserved cases using ANCOVA with treatment and centre as factors, and the modiment and centre as factors, and the modified DESS total score at the start of the fied DESS total score at the start of the wash-out period as a covariate. wash-out period as a covariate.
RESULTS RESULTS

Patient baseline characteristics Patient baseline characteristics
There were no clinically relevant differences There were no clinically relevant differences between groups in patient demographic between groups in patient demographic or clinical characteristics at baseline or clinical characteristics at baseline (Table 1 ). The small differences between (Table 1 ). The small differences between groups in HAMA total score at baseline groups in HAMA total score at baseline are unlikely to be of clinical significance, are unlikely to be of clinical significance, and are adjusted for in the primary efficacy and are adjusted for in the primary efficacy analysis by the inclusion of baseline score analysis by the inclusion of baseline score as a covariate. Most patients were as a covariate. Most patients were Caucasian, and there was an approximately Caucasian, and there was an approximately 2:1 ratio of women to men, with a mean age 2:1 ratio of women to men, with a mean age of about 41 years. Baseline HAMA, CGI-S of about 41 years. Baseline HAMA, CGI-S and MADRS scores indicated a moderately and MADRS scores indicated a moderately to severely ill patient population with a low to severely ill patient population with a low level of depressive symptoms. level of depressive symptoms.
Withdrawals from the study Withdrawals from the study Fig. 1 shows the patient disposition for the Fig. 1 shows the patient disposition for the 14-week study period for all groups. A total 14-week study period for all groups. A total of 98 patients (14%) withdrew from the of 98 patients (14%) withdrew from the study during the 12-week, double-blind study during the 12-week, double-blind period (Table 2) , and withdrawal rates period (Table 2) , and withdrawal rates ranged from 10.8% to 18.7%. ranged from 10.8% to 18.7%.
The proportion of patients that withThe proportion of patients that withdrew because of adverse events was drew because of adverse events was relatively low ( relatively low (5 511% in any treatment 11% in any treatment group and group and 5 57% overall). Compared with 7% overall). Compared with the placebo group, significantly more the placebo group, significantly more patients (chi-square test, patients (chi-square test, P P5 50.05) in the 0.05) in the escitalopram 20 mg and paroxetine 20 mg escitalopram 20 mg and paroxetine 20 mg groups withdrew because of adverse events. groups withdrew because of adverse events. Withdrawal rates due to lack of efficacy Withdrawal rates due to lack of efficacy in the escitalopram 5 and 20 mg, paroxetine in the escitalopram 5 and 20 mg, paroxetine 20 mg and placebo groups were comparable. 20 mg and placebo groups were comparable.
Compared with placebo, significantly fewer Compared with placebo, significantly fewer patients in the escitalopram 10 mg group patients in the escitalopram 10 mg group withdrew because of lack of efficacy. withdrew because of lack of efficacy.
Primary efficacy analysis Primary efficacy analysis
The prospectively defined primary efficacy The prospectively defined primary efficacy end-point (adjusted mean change in HAMA end-point (adjusted mean change in HAMA total score from baseline to week 12, last total score from baseline to week 12, last observation carried forward) showed that observation carried forward) showed that treatment with escitalopram 10 and 20 mg treatment with escitalopram 10 and 20 mg was significantly superior to placebo at was significantly superior to placebo at week 12 (Table 3 and Fig. 2 ). Escitaloweek 12 (Table 3 and Fig. 2 ). Escitalopram 5 mg and paroxetine 20 mg were not pram 5 mg and paroxetine 20 mg were not significantly superior to placebo at week significantly superior to placebo at week 12. 12.
2 6 6 2 6 6 Women, Women, n n (%) (%) 93 (67) 93 (67) 78 (58) 78 (58) 91 (67) 91 (67) 92 (69) 92 (69) 84 (60) 2. Based on intention-to-treat population (see Fig. 1 ).
2. Based on intention-to-treat population (see Fig. 1 ). 
Secondary efficacy analysis Secondary efficacy analysis
CGI^Improvement scores CGI^Improvement scores
The mean CGI-I scores at each visit The mean CGI-I scores at each visit are shown in Fig. 3 . In the observed cases are shown in Fig. 3 . In the observed cases analyses, separation of active treatment analyses, separation of active treatment from placebo was statistically significant from placebo was statistically significant from week 2 onwards for escitalopram 10 from week 2 onwards for escitalopram 10 and 20 mg (ANOVA, and 20 mg (ANOVA, P P5 50.05), including 0.05), including week 12 (last observation carried forward). week 12 (last observation carried forward). Escitalopram 5 mg was statistically signifiEscitalopram 5 mg was statistically significantly superior to placebo at weeks 10 cantly superior to placebo at weeks 10 and 12 (ANOVA, and 12 (ANOVA, P P5 50.05, observed cases) 0.05, observed cases) but not at week 12 (last observation carried but not at week 12 (last observation carried forward). Paroxetine 20 mg was statistiforward). Paroxetine 20 mg was statistically significantly superior to placebo at cally significantly superior to placebo at weeks 4, 8 and 10 (ANOVA, weeks 4, 8 and 10 (ANOVA, P P5 50.05, ob-0.05, observed cases). Escitalopram 10 mg was sigserved cases). Escitalopram 10 mg was significantly superior to paroxetine 20 mg at nificantly superior to paroxetine 20 mg at week 12 (ANOVA, week 12 (ANOVA, P P5 50.05, last obser-0.05, last observation carried forward). vation carried forward).
Response Response
Response based on the Response based on the 5 550% reduction in 50% reduction in HAMA total score criterion was analysed HAMA total score criterion was analysed for each treatment group at each visit by for each treatment group at each visit by 2 6 7 2 6 7 Fig. 4 ). Significant superiority pectively; Fig. 4 ). Significant superiority over placebo was seen from week 2 (obover placebo was seen from week 2 (observed cases) onwards for escitalopram served cases) onwards for escitalopram 10 mg (Fisher's exact test, 10 mg (Fisher's exact test, P P5 50.05; 0.05; Fig. 4 ). The escitalopram 20 mg group Fig. 4) . The escitalopram 20 mg group showed significance (Fisher's exact test, showed significance (Fisher's exact test, P P5 50.05) over placebo from week 4 on-0.05) over placebo from week 4 onwards. Response rates (observed cases) at wards. Response rates (observed cases) at week 12 were 69% (placebo), 77% (escitaweek 12 were 69% (placebo), 77% (escitalopram 5 mg), 83% (escitalopram 10 mg), lopram 5 mg), 83% (escitalopram 10 mg), 84% (escitalopram 20 mg), and 76% (par-84% (escitalopram 20 mg), and 76% (paroxetine 20 mg). The proportion of responoxetine 20 mg). The proportion of responders in the paroxetine 20 mg group was ders in the paroxetine 20 mg group was not significantly different from that in the not significantly different from that in the placebo group at any visit. placebo group at any visit.
Remission Remission
Remission was prospectively defined as a Remission was prospectively defined as a HAMA total score HAMA total score 4 47 and was analysed 7 and was analysed for each treatment group at each visit by for each treatment group at each visit by observed cases and at week 12 also by last observed cases and at week 12 also by last observation carried forward. Fig. 5 ). 0.05; Fig. 5 ).
HAD anxiety sub-scale scores HAD anxiety sub-scale scores
In the analyses of the HAD anxiety subIn the analyses of the HAD anxiety subscale score, separation from placebo was scale score, separation from placebo was statistically significant at both assessments statistically significant at both assessments (weeks 6 and 12) for escitalopram 10 and (weeks 6 and 12) for escitalopram 10 and 20 mg (ANCOVA, 20 mg (ANCOVA, P P5 50.05), whereas esci-0.05), whereas escitalopram 5 mg and paroxetine 20 mg were talopram 5 mg and paroxetine 20 mg were significantly superior to placebo only at significantly superior to placebo only at week 6 (ANCOVA, week 6 (ANCOVA, P P5 50.05; Fig. 6 ). In 0.05; Fig. 6 ). In the last-observation-carried-forward analythe last-observation-carried-forward analysis, escitalopram 10 mg was furthermore sis, escitalopram 10 mg was furthermore significantly (ANCOVA, significantly (ANCOVA, P P5 50.05) superior 0.05) superior to paroxetine 20 mg at week 12. to paroxetine 20 mg at week 12.
Tolerability Tolerability
Adverse events Adverse events Table 4 shows adverse events with an inci- Table 4 shows adverse events with an incidence dence 5 55% in any treatment group during 5% in any treatment group during the 12-week double-blind treatment period; the 12-week double-blind treatment period; there was no statistically significant difthere was no statistically significant difference in the number of patients experienference in the number of patients experiencing adverse events across groups (chicing adverse events across groups (chisquare test). The investigators considered square test). The investigators considered the majority of the adverse events in all the majority of the adverse events in all treatment groups to be mild or moderate. treatment groups to be mild or moderate. The approximate percentage of patients The approximate percentage of patients with adverse events considered to be related with adverse events considered to be related to study medication in each group was: to study medication in each group was: 36% for placebo; 44% for escitalopram 36% for placebo; 44% for escitalopram 5 mg; 54% for escitalopram 10 mg; 53% 5 mg; 54% for escitalopram 10 mg; 53% 2 6 8 2 6 8 for escitalopram 20 mg; and 55% for parfor escitalopram 20 mg; and 55% for paroxetine 20 mg. The incidence of fatigue, oxetine 20 mg. The incidence of fatigue, insomnia, diarrhoea, somnolence, increased insomnia, diarrhoea, somnolence, increased sweating, yawning and anorgasmia were sweating, yawning and anorgasmia were statistically significantly higher in at least statistically significantly higher in at least one treatment group one treatment group v v. placebo (Fisher's . placebo (Fisher's exact test). exact test). Table 5 shows adverse events with an Table 5 shows adverse events with an incidence incidence 5 55% in any treatment group 5% in any treatment group during the wash-out period. In each of the during the wash-out period. In each of the three escitalopram groups, the proportion three escitalopram groups, the proportion of patients with adverse events during this of patients with adverse events during this period was not statistically different from period was not statistically different from that in the placebo group. The proportion that in the placebo group. The proportion of patients in the paroxetine 20 mg group of patients in the paroxetine 20 mg group with adverse events was significantly higher with adverse events was significantly higher (chi-square test, (chi-square test, P P5 50.01) than each of the 0.01) than each of the other active treatment groups. The adverse other active treatment groups. The adverse events that had a statistically (Fisher's exact events that had a statistically (Fisher's exact test, test, P P5 50.05) higher incidence in any active 0.05) higher incidence in any active treatment group treatment group v v. placebo during the . placebo during the wash-out period were: escitalopram 10 mg, wash-out period were: escitalopram 10 mg, insomnia (5.1%); escitalopram 20 mg, insomnia (5.1%); escitalopram 20 mg, vertigo (3.6%); and paroxetine 20 mg, vertigo (3.6%); and paroxetine 20 mg, dizziness (19.5%), nausea (8.0%) and vertidizziness (19.5%), nausea (8.0%) and vertigo (5.3%). Dizziness had a statistically go (5.3%). Dizziness had a statistically significantly higher incidence in the parsignificantly higher incidence in the paroxetine 20 mg group than in any of the oxetine 20 mg group than in any of the escitalopram groups. escitalopram groups. Fig. 7 shows the adjusted mean change Fig. 7 shows the adjusted mean change from the start of the wash-out period in from the start of the wash-out period in the total score on the modified DESS, as the total score on the modified DESS, as assessed by the DESS checklist. The dose assessed by the DESS checklist. The dose received by participants in the escitalopram received by participants in the escitalopram 20 mg group was down-tapered to 10 mg 20 mg group was down-tapered to 10 mg during week 13 and to placebo during week during week 13 and to placebo during week 14, without a randomised withdrawal 14, without a randomised withdrawal design, and results are therefore not predesign, and results are therefore not presented in Fig. 7 . The mean total scores on sented in Fig. 7 . The mean total scores on the modified DESS were at a maximum the modified DESS were at a maximum after 7 days of wash-out treatment for the after 7 days of wash-out treatment for the paroxetine 20 mg group and the 5 and paroxetine 20 mg group and the 5 and 10 mg escitalopram groups. The mean 10 mg escitalopram groups. The mean change in the number of new or worsened change in the number of new or worsened DESS items was statistically significantly DESS items was statistically significantly higher in the paroxetine 20 mg group than higher in the paroxetine 20 mg group than in the placebo group (4.2 in the placebo group (4.2 v v. 0.4; ANCOVA, . 0.4; ANCOVA, P P5 50.001) at day 7. The discontinuation 0.001) at day 7. The discontinuation symptoms were transient and, after a symptoms were transient and, after a further 7 days of wash-out treatment, further 7 days of wash-out treatment, returned to a level only slightly higher than returned to a level only slightly higher than that before starting wash-out treatment. that before starting wash-out treatment.
Discontinuation Emergent Signs and Discontinuation Emergent Signs and Symptoms (DESS) Symptoms (DESS)
DISCUSSION DISCUSSION
The aim of the current study was to examThe aim of the current study was to examine three doses of escitalopram ine three doses of escitalopram v v. placebo . placebo and an active comparator (paroxetine) with and an active comparator (paroxetine) with proven efficacy for the medium-term (12 proven efficacy for the medium-term (12 weeks) treatment of generalised anxiety weeks) treatment of generalised anxiety disorder. The study design also allowed disorder. The study design also allowed detailed evaluation of discontinuation detailed evaluation of discontinuation symptoms, based on the DESS score. The symptoms, based on the DESS score. The baseline HAMA total score of approxibaseline HAMA total score of approximately 27 and the baseline CGI-S score mately 27 and the baseline CGI-S score of approximately 4.5 indicate that this of approximately 4.5 indicate that this study population represents patients with study population represents patients with moderate to severe illness. moderate to severe illness.
There are a number of limitations to There are a number of limitations to this study. First, the presence of the comorthis study. First, the presence of the comorbid disorders typically found in patients bid disorders typically found in patients with generalised anxiety disorder was low, with generalised anxiety disorder was low, as required by the protocol, and the results as required by the protocol, and the results of this study are potentially less generalisof this study are potentially less generalisable to samples seen in other clinical able to samples seen in other clinical settings, settings, although escitalopram has proven although escitalopram has proven efficacy in major depression (Burke efficacy in major depression (Burke et al et al, , 2002; Lepola 2002; Lepola et al et al, 2003) , the most com-, 2003), the most common comorbid disorder in generalised anximon comorbid disorder in generalised anxiety. ety. Second, the placebo response rate Second, the placebo response rate ( (4 460%) 60%) is high, when compared with is high, when compared with 2 6 9 2 6 9 , 2006) . The high response rate to placebo in this investigaresponse rate to placebo in this investigation may result from the combination of tion may result from the combination of the five-arm study design, the inclusion of the five-arm study design, the inclusion of multiple study centres and the frequency multiple study centres and the frequency of study assessments. Third, there was no of study assessments. Third, there was no taper from 20 mg to 10 mg of paroxetine taper from 20 mg to 10 mg of paroxetine during the wash-out period, reflecting treatduring the wash-out period, reflecting treatment recommendations at the time of the ment recommendations at the time of the study. A fourth potential limitation lies study. A fourth potential limitation lies within the method within the method of analysis. It has been of analysis. It has been argued that lastargued that last-observation-carried-for-observation-carried-forward analysis is not the best approach for ward analysis is not the best approach for evaluating data from randomised conevaluating data from randomised controlled trials (White trolled trials (White et al et al, 2003; Everitt , 2003; Everitt & Wessely, 2004) . All methods for the & Wessely, 2004). All methods for the imputation of missing data have their imputation of missing data have their limitations, but in disorders that do not limitations, but in disorders that do not deteriorate progressively, the conservative deteriorate progressively, the conservative approach adopted in the above analysis is approach adopted in the above analysis is favoured by regulatory bodies, and was favoured by regulatory bodies, and was the specified form of data analysis in the the specified form of data analysis in the study protocol. study protocol.
The primary efficacy analysis (mean The primary efficacy analysis (mean change from baseline in HAMA total score change from baseline in HAMA total score at week 12 using last observation carried at week 12 using last observation carried forward) showed that escitalopram 10 and forward) showed that escitalopram 10 and 20 mg were significantly superior to pla-20 mg were significantly superior to placebo. A dose-response relationship was cebo. A dose-response relationship was seen at week 12 in the observed cases anaseen at week 12 in the observed cases analysis. All three escitalopram doses were siglysis. All three escitalopram doses were significantly superior to placebo; however, nificantly superior to placebo; however, there was an increasing robustness of signifthere was an increasing robustness of significance icance v v. placebo from escitalopram 5 mg . placebo from escitalopram 5 mg to 20 mg, which was associated with the to 20 mg, which was associated with the highest response. Escitalopram 20 mg was highest response. Escitalopram 20 mg was also superior to paroxetine 20 mg in the obalso superior to paroxetine 20 mg in the observed cases analysis. The last-observationserved cases analysis. The last-observationcarried-forward analysis demonstrated that carried-forward analysis demonstrated that escitalopram 10 mg was also significantly escitalopram 10 mg was also significantly superior to superior to paroxetine 20 mg at week 12.
paroxetine 20 mg at week 12. Mean HAMA and CGI-S scores decreased Mean HAMA and CGI-S scores decreased from week 10 to week 12, indicating that from week 10 to week 12, indicating that continued treatment might have resulted in continued treatment might have resulted in further improvement, as found in a relapsefurther improvement, as found in a relapseprevention study (Allgulander prevention study (Allgulander et al et al, 2005) , , 2005), although only responders to acute treatment although only responders to acute treatment were eligible to continue in that study. were eligible to continue in that study.
Paroxetine, 20 mg failed to show a Paroxetine, 20 mg failed to show a significant difference from placebo in the significant difference from placebo in the primary efficacy analysis, which is probably primary efficacy analysis, which is probably attributable to the high response to placebo attributable to the high response to placebo (Fig. 4) . However, the decrease in HAMA (Fig. 4) . However, the decrease in HAMA from baseline to week 12 with paroxetine from baseline to week 12 with paroxetine was approximately 14 points, numerically was approximately 14 points, numerically greater than placebo, and similar to that greater than placebo, and similar to that described in a previous study (Rickels described in a previous study (Rickels et et al al, 2003) , where paroxetine 20 mg for 8 , 2003) , where paroxetine 20 mg for 8 2 7 0 2 7 0 Abdominal pain Abdominal pain 5 (3.6) 5 (3.6) 6 (4.5) 6 (4.5) 4 (2.9) 4 (2.9) 4 (3.0) 4 (3.0) 9 (6.5) 9 (6.5) Anxiety Anxiety 4 (2.9) 4 (2.9) 9 (6.7) 9 (6.7) 3 (2.2) 3 (2.2) 4 (3.0) 4 (3.0) 6 (4.3) 6 (4.3)
Back pain Back pain 4 (2.9) 4 (2.9) 4 (3.0) 4 (3.0) 7 (5.1) 7 (5.1) 4 (3.0) 4 (3.0) 5 (3.6) 5 (3.6) Anorgasmia Anorgasmia^2 (1.5) 2 (1.5) 6 (4.4)* 6 (4.4)* 2 (1.5) 2 (1.5) 9 (6.5)* 9 (6.5)* weeks resulted in a 12.5-point reduction in weeks resulted in a 12.5-point reduction in the total HAMA score, and paroxetine the total HAMA score, and paroxetine 40 mg in a reduction of 12.2 points. In 40 mg in a reduction of 12.2 points. In our study, paroxetine appeared efficacious our study, paroxetine appeared efficacious on some of the secondary outcome meaon some of the secondary outcome measures: for example, it was significantly sures: for example, it was significantly superior to placebo on the CGI-I at several superior to placebo on the CGI-I at several points.
points. There were a number of secondary There were a number of secondary outcome measures, including the CGI-I, outcome measures, including the CGI-I, response and remission rates and the response and remission rates and the HAD anxiety sub-scale score. Using the HAD anxiety sub-scale score. Using the CGI-I, in the observed cases analysis, the CGI-I, in the observed cases analysis, the escitalopram 10 and 20 mg doses were escitalopram 10 and 20 mg doses were superior to placebo from week 2 onwards, superior to placebo from week 2 onwards, as well as at week 12 using last observation as well as at week 12 using last observation carried forward. According to response cricarried forward. According to response criteria, escitalopram 10 mg was superior to teria, escitalopram 10 mg was superior to placebo from week 2 onwards and, at the placebo from week 2 onwards and, at the end of the study, escitalopram 10 and end of the study, escitalopram 10 and 20 mg doses were significantly more effica-20 mg doses were significantly more efficacious cious than placebo. In the than placebo. In the last-obserlast-observation-carried-forward analysis, the vation-carried-forward analysis, the response rate for the escitalopram 10 mg response rate for the escitalopram 10 mg was also superior to paroxetine 20 mg. Acwas also superior to paroxetine 20 mg. According to remission criteria, escitalopram cording to remission criteria, escitalopram 10 and 20 mg doses were more efficacious 10 and 20 mg doses were more efficacious than placebo from week 8 onwards. Paroxthan placebo from week 8 onwards. Paroxetine 20 mg did not separate from placebo etine 20 mg did not separate from placebo at any time point in this analysis. At study at any time point in this analysis. At study end, all three doses of escitalopram were end, all three doses of escitalopram were superior to placebo and, in the last superior to placebo and, in the last observation analysis, escitalopram 10 mg observation analysis, escitalopram 10 mg was superior to paroxetine 20 mg. was superior to paroxetine 20 mg.
For the self-rating HAD anxiety subFor the self-rating HAD anxiety subscale score, escitalopram 10 and 20 mg scale score, escitalopram 10 and 20 mg were significantly better than placebo at were significantly better than placebo at weeks 6 and 12. In the weeks 6 and 12. In the last-observationlast-observationcarried-forward analysis, at 12 weeks carried-forward analysis, at 12 weeks escitalopram 10 mg was also superior to escitalopram 10 mg was also superior to paroxetine 20 mg. This analysis showed a paroxetine 20 mg. This analysis showed a close agreement between the investigator's close agreement between the investigator's and the patient's assessment of treatment and the patient's assessment of treatment outcome. outcome.
Escitalopram 5 mg was not significantly Escitalopram 5 mg was not significantly superior to placebo across a variety of superior to placebo across a variety of primary and secondary measures. This indiprimary and secondary measures. This indicates that escitalopram 5 mg is probably cates that escitalopram 5 mg is probably too low a dose in this population of too low a dose in this population of patients with generalised anxiety disorder. patients with generalised anxiety disorder. Higher doses are more efficacious, with an Higher doses are more efficacious, with an increased benefit for 20 mg, especially in increased benefit for 20 mg, especially in terms of reaching symptomatic remission. terms of reaching symptomatic remission.
The incidence of adverse events during The incidence of adverse events during the 12-week study period was similar the 12-week study period was similar across all treatment groups. The proportion across all treatment groups. The proportion of patients with adverse events and withof patients with adverse events and withdrawals due to adverse events tended to drawals due to adverse events tended to increase as the dose of escitalopram inincrease as the dose of escitalopram increased. Only in the highest escitalopram creased. Only in the highest escitalopram dose group was there a significant differdose group was there a significant difference in withdrawals due to adverse events ence in withdrawals due to adverse events compared with withdrawals with the placompared with withdrawals with the placebo group, as was the case in the paroxecebo group, as was the case in the paroxetine 20 mg group. The adverse events that tine 20 mg group. The adverse events that were reported during the 12-week treatwere reported during the 12-week treatment period for both escitalopram and ment period for both escitalopram and paroxetine were characteristic for SSRIs. paroxetine were characteristic for SSRIs. The incidence of patients reporting such The incidence of patients reporting such events during the wash-out period was sigevents during the wash-out period was significantly higher in the paroxetine 20 mg nificantly higher in the paroxetine 20 mg group compared with escitalopram and group compared with escitalopram and placebo. The most frequent adverse event placebo. The most frequent adverse event during wash-out was dizziness, which was during wash-out was dizziness, which was reported by almost one-fifth of patients reported by almost one-fifth of patients (22 out of 113) in the paroxetine group. (22 out of 113) in the paroxetine group.
After 7 days of wash-out treatment, After 7 days of wash-out treatment, patients in the paroxetine 20 mg group patients in the paroxetine 20 mg group were significantly more likely to have were significantly more likely to have discontinuation-emergent symptoms comdiscontinuation-emergent symptoms compared with those in the placebo group. pared with those in the placebo group. Patients who stopped treatment with escitaPatients who stopped treatment with escitalopram 10 mg had fewer discontinuation lopram 10 mg had fewer discontinuation effects than those who stopped treatment effects than those who stopped treatment with paroxetine 20 mg, this being conwith paroxetine 20 mg, this being consistent with the findings of a similar sistent with the findings of a similar placebo-controlled study in social phobia placebo-controlled study in social phobia (Lader (Lader et al et al, 2004) . The discontinuation , 2004). The discontinuation symptoms in the DESS checklist were symptoms in the DESS checklist were transient and (after a further 7 days of transient and (after a further 7 days of wash-out treatment with placebo) returned wash-out treatment with placebo) returned to a level similar to that before patients to a level similar to that before patients started wash-out treatment. There was no started wash-out treatment. There was no significant difference between the escitalosignificant difference between the escitalopram 5 mg and 10 mg groups pram 5 mg and 10 mg groups v v. placebo . placebo based on the modified DESS total score. based on the modified DESS total score. In view of this, and the lower number of In view of this, and the lower number of patients withdrawn because of adverse patients withdrawn because of adverse events in the escitalopram 10 mg group, events in the escitalopram 10 mg group, clinicians may prefer to start with a 10 mg clinicians may prefer to start with a 10 mg dose, increasing to 20 mg if patients show dose, increasing to 20 mg if patients show no signs of response after 4 weeks of treatno signs of response after 4 weeks of treatment, when a significant difference from ment, when a significant difference from response to placebo was first seen in this response to placebo was first seen in this study (Fig. 2) . study (Fig. 2) .
In summary, escitalopram (10 and In summary, escitalopram (10 and 20 mg/day) was efficacious and well toler-20 mg/day) was efficacious and well tolerated in the medium-term treatment of ated in the medium-term treatment of generalised anxiety disorder. Escitalopram generalised anxiety disorder. Escitalopram 10 mg was significantly more efficacious 10 mg was significantly more efficacious than paroxetine 20 mg. than paroxetine 20 mg.
